Some Old Drugs Improve Late Primary Patency Rate of Native Arteriovenous Fistulas in Hemodialysis Patients

Annals of Vascular Surgery

Volumn 23, Issue 4, 2009, Pages 491-497

  Righetti, Marco ^a   Ferrario, GianMichele ^a   Serbelloni, Paola ^a   Milani, Silvana ^a   Tommasi, Adalberto ^a  

^a DESIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; TICLOPIDINE; VITAMIN D;

AGED; ARTERIOVENOUS FISTULA; ARTERY INTIMA PROLIFERATION; ARTICLE; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; EVENT FREE SURVIVAL; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VASCULAR ACCESS; VASCULAR PATENCY;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOVENOUS SHUNT, SURGICAL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIETARY SUPPLEMENTS; FOLIC ACID; GRAFT OCCLUSION, VASCULAR; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERPLASIA; LOGISTIC MODELS; PLATELET AGGREGATION INHIBITORS; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 67349253387     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2008.08.033     Document Type: Article

References (30)

1. Rayner H.C., Pisoni R.L., Bommer J., et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 (2004) 108-120
2. Schwab S.J., Harrington J.T., Singh A., et al. Vascular access for hemodialysis. Kidney Int 55 (1999) 2078-2090
3. Roy-Chaudhury P., Sukhatme V.P., and Cheung A.K. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol 17 (2006) 1112-1127
4. Ravani P., Brunori G., Mandolfo S., et al. Cardiovascular comorbidity and late referral impact arteriovenous fistula survival: a prospective multicenter study. J Am Soc Nephrol 15 (2004) 204-209
5. Ravani P., Barrett B., Mandolfo S., et al. Factors associated with unsuccessful utilization and early failure of the arteriovenous fistula for hemodialysis. J Nephrol 18 (2005) 188-196
6. Roy-Chaudhury P., Kelly B.S., Zhang J., et al. Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies. Blood Purif 21 (2003) 99-110
7. Righetti M., Serbelloni P., Milani S., and Ferrario G.M. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 24 (2006) 379-386
8. Yap S., Boers G.H.J., Wilcken B., et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically. A multicenter observational study. Arterioscler Thromb Vasc Biol 21 (2001) 2080-2085
9. Yang Q., Botto L.D., Erickson J.D., et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 13 (2006) 1335-1343
10. Wang X., Qin X., Demirtas H., et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369 (2007) 1876-1882
11. Righetti M. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Clin Chem Lab Med 45 (2007) 1586-1589
12. Mallamaci F., Bonanno G., Seminara G., et al. Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. Am J Kidney Dis 45 (2005) 702-707
13. Righetti M. Folate metabolism dysfunction. G Ital Nefrol 25 (2008) 32-41
14. Righetti M., Tommasi A., Lagona C., La Rosa L., Uccellini M., and Sessa A. Effective homocysteine-lowering vitamin B treatment in peritoneal dialysis patients. Perit Dial Int 24 (2004) 373-377
15. Righetti M., Ferrario G.M., Serbelloni P., Milani S., and Tommasi A. Homocysteine reduction rate in internal haemodiafiltration: a comparison with other mixed dialysis therapies. Nephrol Dial Transplant 21 (2006) 2034-2035
16. Beerenhout C., Luik A.J., Jeuken-Mertens S.G.J., et al. Pre-dilution on-line haemofiltration vs. low flux haemodialysis: a randomised prospective study. Nephrol Dial Transplant 20 (2005) 1155-1163
17. Friedman A.N., Bostom A.G., Levy A.S., Rosenberg I.H., Selhub J., and Pierratos A. Plasma total homocysteine levels among patients undergoing nocturnal vs. standard hemodialysis. J Am Soc Nephrol 13 (2002) 265-268
18. Scholze A., Rinder C., Beige J., Riezler R., Zidek W., and Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end stage renal failure. Circulation 109 (2004) 369-374
19. Righetti M. Homocysteine and folate therapy in dialysis patients. Lett Drug Des Discov 3 (2006) 351-355
20. Vaughan C.J., Gotto A.M., and Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35 (2000) 1-10
21. Wiesbauer F., Kaun C., Zorn G., Maurer G., Huber K., and Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 135 (2002) 284-292
22. Szmitko P.E., Fedak P.W., Weisel R.D., Stewart D.J., Kutryk M.J., and Verma S. Endothelial progenitor cells: new hope for a broken heart. Circulation 107 (2003) 3093-3100
23. Saran R., Dykstra D.M., Wolfe R.A., Gillespie B., Held P.J., and Young E.W. Dialysis Outcomes and Practice Patterns Study. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 40 (2002) 1255-1263
24. Gradzki R., Dhingra R.K., Port F.K., Roys E., Weitzel W.F., and Messana J.M. Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis 38 (2001) 1240-1244
25. Garrancho J.M., Kirchgessner J., Arranz M., et al. Haemoglobin level and vascular access survival in haemodialysis patients. Nephrol Dial Transplant 20 (2005) 2453-2457
26. Kaufman J.S., O'Connor T.Z., Zhang J.H., et al. Veterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14 (2003) 2313-2321
27. Gröntoft K.C., Larsson R., Mulec H., Weiss L.G., and Dickinson J.P. Effects of ticlopidine in arteriovenous fistula surgery in uremia. Fistula Study Group. Scand J Urol Nephrol 32 (1998) 276-283
28. Dember L.M., Beck G.J., Allon M., and Dialysis. Access Consortium (DAC) Study Group. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. J A M A 299 (2008) 2164-2171
29. Roy-Chaudhury P., Kelly B.S., Miller M.A., et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 59 (2001) 2325-2334
30. Fuster V., Charlton P., and Boyd A. Clinical protocol. A phase IIb, randomized, multicenter, double blind study of the efficacy of Trinam (EG004) in stenosis prevention at the graft-vein anastomosis site in dialysis patient. Hum Gene Ther 12 (2001) 2025-2027